Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
All of the recent problems have caused the company’s largest shareholder to push for a sale.
Analysts feel the company’s profit potential is starting to improve following a year in which its shares fell by more than 21%.
Investors and analysts have given it some thought and mostly think it’s a sensible acquisition.
Chinese interest in the J&J unit comes as the market for diabetes care in China is expected to grow rapidly.
resTORbio is developing novel therapies to improve immune function in the elderly.
The rumors have caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
Speculation around a possible bid has mounted in recent months.
The Suzhou-based cancer-drug maker has been discussing a valuation of more than $1 billion.
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Lilly’s CEO noted at JPM that the recent tax changes should free up cash for more M&As.